(Reuters) -Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...
With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.
After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...
2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...
Brian Skorney has given his Hold rating due to a combination of factors impacting Regeneron’s outlook. A significant concern is Amgen’s intent to launch a biosimilar to Regeneron’s leading ...
Given Regeneron’s failure to secure a stay against Amgen’s (AMGN) Eylea biosimilar, the firm thinks the base case should be that Amgen launch is imminent. However, Wells thinks Regeneron is ...
Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback